The epidemiological hip fracture leads to a high death rate in the elderly with
osteoporosis worldwide. However, the appropriate surgical styles or anti-osteoporotic
therapy could prevent these patients with
hip fractures from suffering refracture, but the efficacy of such treatment remains elusive for first hip fractured patients. Our retrospective analysis was conducted on 508 hip fracture patients who were enrolled from Show Chwan Memorial Hospital from January 2005 through December 2011 and followed up until the end of 2012. However, bipolar
hemiarthroplasty replacement and open reduction internal fixation (ORIF) are treatment options for femoral neck and intertrochanic hip fracture in our study population. Among these patients, 82 suffered 2nd hip fracture (refracture) with femoral neck or intertrochanteric fracture and 39 died after surgical intervention accompanied complications. Kaplan-Meier analysis revealed a better outcome in patients with bipolar
hemiarthroplasty replacement or
fosamax therapy of hip fractured patients than those with femoral neck/ORIF and intertrochanteric/ORIF or without
fosamax therapy. Multivariate cox regression analysis revealed the lowest incidence of refracture and mortality in hip fracture patients with received bipolar
hemiarthroplasty replacement surgical intervention (OR=0.732, CI=0.587-0.912; P=0.006). It is therefore concluded that
fosamax therapy may improve bone density and increase bone tissue repair to prevent patients with hip fracture from refracture, and bipolar
hemiarthroplasty replacement may promote patients who undertake outdoor activities to produce more
vitamin D than those who have received ORIF.